218 related articles for article (PubMed ID: 2139701)
1. Active-specific immunotherapy for melanoma.
Mitchell MS; Harel W; Kempf RA; Hu E; Kan-Mitchell J; Boswell WD; Dean G; Stevenson L
J Clin Oncol; 1990 May; 8(5):856-69. PubMed ID: 2139701
[TBL] [Abstract][Full Text] [Related]
2. Active immunotherapy with ultraviolet B-irradiated autologous whole melanoma cells plus DETOX in patients with metastatic melanoma.
Eton O; Kharkevitch DD; Gianan MA; Ross MI; Itoh K; Pride MW; Donawho C; Buzaid AC; Mansfield PF; Lee JE; Legha SS; Plager C; Papadopoulos NE; Bedikian AY; Benjamin RS; Balch CM
Clin Cancer Res; 1998 Mar; 4(3):619-27. PubMed ID: 9533529
[TBL] [Abstract][Full Text] [Related]
3. Active specific immunotherapy for melanoma: phase I trial of allogeneic lysates and a novel adjuvant.
Mitchell MS; Kan-Mitchell J; Kempf RA; Harel W; Shau HY; Lind S
Cancer Res; 1988 Oct; 48(20):5883-93. PubMed ID: 3262416
[TBL] [Abstract][Full Text] [Related]
4. Active specific immunotherapy of melanoma with allogeneic cell lysates. Rationale, results, and possible mechanisms of action.
Mitchell MS; Harel W; Kan-Mitchell J; LeMay LG; Goedegebuure P; Huang XQ; Hofman F; Groshen S
Ann N Y Acad Sci; 1993 Aug; 690():153-66. PubMed ID: 8368734
[TBL] [Abstract][Full Text] [Related]
5. Effect of DETOX as an adjuvant for melanoma vaccine.
Schultz N; Oratz R; Chen D; Zeleniuch-Jacquotte A; Abeles G; Bystryn JC
Vaccine; 1995 Apr; 13(5):503-8. PubMed ID: 7639018
[TBL] [Abstract][Full Text] [Related]
6. Increased effectiveness of interferon alfa-2b following active specific immunotherapy for melanoma.
Mitchell MS; Jakowatz J; Harel W; Dean G; Stevenson L; Boswell WD; Groshen S
J Clin Oncol; 1994 Feb; 12(2):402-11. PubMed ID: 8113848
[TBL] [Abstract][Full Text] [Related]
7. Active immunotherapy of metastatic melanoma with allogeneic melanoma lysates and interferon alpha.
Vaishampayan U; Abrams J; Darrah D; Jones V; Mitchell MS
Clin Cancer Res; 2002 Dec; 8(12):3696-701. PubMed ID: 12473578
[TBL] [Abstract][Full Text] [Related]
8. Melanoma-reactive human cytotoxic T lymphocytes derived from skin biopsies of delayed-type hypersensitivity reactions induced by injection of an autologous melanoma cell line.
Waanders GA; Rimoldi D; Liénard D; Carrel S; Lejeune F; Dietrich PY; Cerottini JC; Romero P
Clin Cancer Res; 1997 May; 3(5):685-96. PubMed ID: 9815737
[TBL] [Abstract][Full Text] [Related]
9. Attempts to optimize active specific immunotherapy for melanoma.
Mitchell MS
Int Rev Immunol; 1991; 7(4):331-47. PubMed ID: 1779176
[TBL] [Abstract][Full Text] [Related]
10. Phase I trial of large multivalent immunogen derived from melanoma lysates in patients with disseminated melanoma.
Mitchell MS; Kan-Mitchell J; Morrow PR; Darrah D; Jones VE; Mescher MF
Clin Cancer Res; 2004 Jan; 10(1 Pt 1):76-83. PubMed ID: 14734454
[TBL] [Abstract][Full Text] [Related]
11. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
[TBL] [Abstract][Full Text] [Related]
12. Active immunotherapy of human melanoma exploiting the immunopotentiating effects of cyclophosphamide.
Berd D; Mastrangelo MJ
Cancer Invest; 1988; 6(3):337-49. PubMed ID: 3167614
[TBL] [Abstract][Full Text] [Related]
13. Vaccination of melanoma patients with an allogeneic, genetically modified interleukin 2-producing melanoma cell line.
Osanto S; Schiphorst PP; Weijl NI; Dijkstra N; Van Wees A; Brouwenstein N; Vaessen N; Van Krieken JH; Hermans J; Cleton FJ; Schrier PI
Hum Gene Ther; 2000 Mar; 11(5):739-50. PubMed ID: 10757353
[TBL] [Abstract][Full Text] [Related]
14. Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings.
Belli F; Testori A; Rivoltini L; Maio M; Andreola G; Sertoli MR; Gallino G; Piris A; Cattelan A; Lazzari I; Carrabba M; Scita G; Santantonio C; Pilla L; Tragni G; Lombardo C; Arienti F; Marchianò A; Queirolo P; Bertolini F; Cova A; Lamaj E; Ascani L; Camerini R; Corsi M; Cascinelli N; Lewis JJ; Srivastava P; Parmiani G
J Clin Oncol; 2002 Oct; 20(20):4169-80. PubMed ID: 12377960
[TBL] [Abstract][Full Text] [Related]
15. Polyvalent melanoma cell vaccine induces delayed-type hypersensitivity and in vitro cellular immune response.
Barth A; Hoon DS; Foshag LJ; Nizze JA; Famatiga E; Okun E; Morton DL
Cancer Res; 1994 Jul; 54(13):3342-5. PubMed ID: 8012946
[TBL] [Abstract][Full Text] [Related]
16. Phase I study of adoptive T-cell therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanoma.
Mackensen A; Meidenbauer N; Vogl S; Laumer M; Berger J; Andreesen R
J Clin Oncol; 2006 Nov; 24(31):5060-9. PubMed ID: 17075125
[TBL] [Abstract][Full Text] [Related]
17. [Response in patients with melanoma to immunization using melanoma oncolysates of vaccine virus].
Doré JF; Portoukalian J; Berthier-Vergnes O; Jacubovich R; Genève J; Bailly M; Lefthériotis E; Weissbrod A; Mayer M
Bull Cancer; 1990; 77(9):881-91. PubMed ID: 2224160
[TBL] [Abstract][Full Text] [Related]
18. Sustained regression of a primary choroidal melanoma under the influence of a therapeutic melanoma vaccine.
Mitchell MS; Liggett PE; Green RL; Kan-Mitchell J; Murphree AL; Dean G; Spears L; Walonker F
J Clin Oncol; 1994 Feb; 12(2):396-401. PubMed ID: 8113847
[TBL] [Abstract][Full Text] [Related]
19. Immune response to polyvalent melanoma cell vaccine in AJCC stage III melanoma: an immunologic survival model.
Jones RC; Kelley M; Gupta RK; Nizze JA; Yee R; Leopoldo Z; Qi K; Stern S; Morton DL
Ann Surg Oncol; 1996 Sep; 3(5):437-45. PubMed ID: 8876885
[TBL] [Abstract][Full Text] [Related]
20. Perspective on allogeneic melanoma lysates in active specific immunotherapy.
Mitchell MS
Semin Oncol; 1998 Dec; 25(6):623-35. PubMed ID: 9865677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
